{"id":70054,"date":"2026-04-13T12:43:05","date_gmt":"2026-04-13T07:13:05","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=70054"},"modified":"2026-04-13T12:43:07","modified_gmt":"2026-04-13T07:13:07","slug":"blogs-dr-reddys-target-share-price-target-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/blogs-dr-reddys-target-share-price-target-2026\/","title":{"rendered":"Dr Reddy&#8217;s Laboratories Share Price Target 2026: Analyst Consensus, Bull Case &amp; Bear Case"},"content":{"rendered":"<p>Dr Reddy&#8217;s Laboratories (Pharmaceuticals) is trading at Rs 1,160 as of April 2026, with a 52-week range from Rs 1,000 to Rs 1,380 and a 1-year return of -10%. The analyst consensus 12-month Dr Reddy&#8217;s Laboratories share price target stands at Rs 1,350-1,600 \u2014 implying meaningful potential movement from current levels.<\/p><p>Whether you are a long-term holder reassessing your position or a new investor evaluating entry levels, understanding where analysts see Dr Reddy&#8217;s Laboratories heading over the next 12-24 months requires looking beyond the CMP. This article covers the key catalysts and risks, technical levels, institutional positioning, and a structured breakdown of the short-term, 12-month, and long-term Dr Reddy&#8217;s Laboratories share price targets.<\/p><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here \u2014 Get Free Investment Predictions on Univest<\/strong><\/a>.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/blogs-dr-reddys-target-share-price-target-2026\/#Dr_Reddys_Laboratories_Key_Data_%E2%80%94_CMP_Valuation_Fundamentals\" title=\"Dr Reddy&#8217;s Laboratories Key Data \u2014 CMP, Valuation, Fundamentals\">Dr Reddy&#8217;s Laboratories Key Data \u2014 CMP, Valuation, Fundamentals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/blogs-dr-reddys-target-share-price-target-2026\/#Dr_Reddys_Laboratories_Share_Price_Targets_%E2%80%94_Short-Term_12-Month_Long-Term\" title=\"Dr Reddy&#8217;s Laboratories Share Price Targets \u2014 Short-Term, 12-Month &amp; Long-Term\">Dr Reddy&#8217;s Laboratories Share Price Targets \u2014 Short-Term, 12-Month &amp; Long-Term<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/blogs-dr-reddys-target-share-price-target-2026\/#Bull_Case_%E2%80%94_What_Has_to_Go_Right_for_Dr_Reddys_Laboratories\" title=\"Bull Case \u2014 What Has to Go Right for Dr Reddy&#8217;s Laboratories\">Bull Case \u2014 What Has to Go Right for Dr Reddy&#8217;s Laboratories<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/blogs-dr-reddys-target-share-price-target-2026\/#1_Biosimilar_portfolio_Rituximab_Bevacizumab_Filgrastim_ramping_in_US_and_Europe\" title=\"1. Biosimilar portfolio (Rituximab, Bevacizumab, Filgrastim) ramping in US and Europe\">1. Biosimilar portfolio (Rituximab, Bevacizumab, Filgrastim) ramping in US and Europe<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/blogs-dr-reddys-target-share-price-target-2026\/#2_Siromus_Sirolimus_approved_for_US\" title=\"2. Siromus (Sirolimus) approved for US\">2. Siromus (Sirolimus) approved for US<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/blogs-dr-reddys-target-share-price-target-2026\/#3_India_branded_generics_growing_12\" title=\"3. India branded generics growing 12%\">3. India branded generics growing 12%<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/blogs-dr-reddys-target-share-price-target-2026\/#4_EBITDA_margin_above_25_as_biosimilar_mix_improves\" title=\"4. EBITDA margin above 25% as biosimilar mix improves\">4. EBITDA margin above 25% as biosimilar mix improves<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/blogs-dr-reddys-target-share-price-target-2026\/#5_At_18x_PE\" title=\"5. At 18x P\/E\">5. At 18x P\/E<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/blogs-dr-reddys-target-share-price-target-2026\/#Bear_Case_%E2%80%94_Key_Risks_to_the_Dr_Reddys_Laboratories_Share_Price_Target\" title=\"Bear Case \u2014 Key Risks to the Dr Reddy&#8217;s Laboratories Share Price Target\">Bear Case \u2014 Key Risks to the Dr Reddy&#8217;s Laboratories Share Price Target<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/blogs-dr-reddys-target-share-price-target-2026\/#Risk_1_US_generic_price_erosion_continuing_to_pressure_base_business_revenue\" title=\"Risk 1: US generic price erosion continuing to pressure base business revenue\">Risk 1: US generic price erosion continuing to pressure base business revenue<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/blogs-dr-reddys-target-share-price-target-2026\/#Risk_2_Biosimilar_market_becoming_competitive_as_Biocon_Mylan_and_Pfizer_all_compete_in_same_molecules\" title=\"Risk 2: Biosimilar market becoming competitive as Biocon, Mylan, and Pfizer all compete in same molecules\">Risk 2: Biosimilar market becoming competitive as Biocon, Mylan, and Pfizer all compete in same molecules<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/blogs-dr-reddys-target-share-price-target-2026\/#Institutional_Sentiment_and_Technical_Analysis\" title=\"Institutional Sentiment and Technical Analysis\">Institutional Sentiment and Technical Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/blogs-dr-reddys-target-share-price-target-2026\/#Conclusion_%E2%80%94_Our_View_on_name_Share_Price_Target\" title=\"Conclusion \u2014 Our View on ${name} Share Price Target\">Conclusion \u2014 Our View on ${name} Share Price Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/blogs-dr-reddys-target-share-price-target-2026\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/blogs-dr-reddys-target-share-price-target-2026\/#Q1_What_is_Dr_Reddys_Laboratories_share_price_target_2026\" title=\"Q1. What is Dr Reddy&#8217;s Laboratories share price target 2026?\">Q1. What is Dr Reddy&#8217;s Laboratories share price target 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/blogs-dr-reddys-target-share-price-target-2026\/#Q2_Is_Dr_Reddys_Laboratories_a_good_buy_now\" title=\"Q2. Is Dr Reddy&#8217;s Laboratories a good buy now?\">Q2. Is Dr Reddy&#8217;s Laboratories a good buy now?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/blogs-dr-reddys-target-share-price-target-2026\/#Q3_What_is_Dr_Reddys_Laboratoriess_current_valuation\" title=\"Q3. What is Dr Reddy&#8217;s Laboratories&#8217;s current valuation?\">Q3. What is Dr Reddy&#8217;s Laboratories&#8217;s current valuation?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/blogs-dr-reddys-target-share-price-target-2026\/#Q4_What_are_the_key_risks_for_Dr_Reddys_Laboratories\" title=\"Q4. What are the key risks for Dr Reddy&#8217;s Laboratories?\">Q4. What are the key risks for Dr Reddy&#8217;s Laboratories?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/blogs-dr-reddys-target-share-price-target-2026\/#Q5_Where_can_I_track_Dr_Reddys_Laboratories_share_price_live\" title=\"Q5. Where can I track Dr Reddy&#8217;s Laboratories share price live?\">Q5. Where can I track Dr Reddy&#8217;s Laboratories share price live?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/blogs-dr-reddys-target-share-price-target-2026\/#Recent_Articles\" title=\"Recent Articles\">Recent Articles<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Dr_Reddys_Laboratories_Key_Data_%E2%80%94_CMP_Valuation_Fundamentals\"><\/span><strong>Dr Reddy&#8217;s Laboratories Key Data \u2014 CMP, Valuation, Fundamentals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Parameter<\/strong><\/td><td><strong>Value<\/strong><\/td><\/tr><tr><td>CMP (April 2026)<\/td><td>Rs 1,160<\/td><\/tr><tr><td>52-Week High<\/td><td>Rs 1,380<\/td><\/tr><tr><td>52-Week Low<\/td><td>Rs 1,000<\/td><\/tr><tr><td>1-Year Return<\/td><td>-10%<\/td><\/tr><tr><td>Trailing P\/E<\/td><td>18x<\/td><\/tr><tr><td>Price-to-Book<\/td><td>2.8x<\/td><\/tr><tr><td>Market Cap<\/td><td>Rs 97,000 Cr<\/td><\/tr><tr><td>Sector<\/td><td>Pharmaceuticals<\/td><\/tr><tr><td>Promoter Holding<\/td><td>26.7%<\/td><\/tr><tr><td>FII Holding<\/td><td>20.4%<\/td><\/tr><tr><td>DII Holding<\/td><td>22.6%<\/td><\/tr><\/tbody><\/table><\/figure><p>Track live <strong>Dr Reddy&#8217;s Laboratories<\/strong> fundamentals and analyst ratings on the <a href=\"https:\/\/univest.in\/screeners\"><strong>Univest Screener<\/strong><\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Dr_Reddys_Laboratories_Share_Price_Targets_%E2%80%94_Short-Term_12-Month_Long-Term\"><\/span><strong>Dr Reddy&#8217;s Laboratories Share Price Targets \u2014 Short-Term, 12-Month &amp; Long-Term<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Access premium analyst research on Univest<\/strong><\/a>.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Scenario<\/strong><\/td><td><strong>Target<\/strong><\/td><td><strong>Basis<\/strong><\/td><\/tr><tr><td>Short-Term (3-6M)<\/td><td>Rs 1,350<\/td><td>Technical support; near-term catalyst<\/td><\/tr><tr><td>12-Month Consensus<\/td><td>Rs 1,350-1,600<\/td><td>Analyst consensus based on current fundamentals<\/td><\/tr><tr><td>Bull Case (FY28)<\/td><td>Rs 2,000<\/td><td>Full execution of growth catalysts below<\/td><\/tr><tr><td>Bear Case<\/td><td>Rs 950<\/td><td>Materialisation of key risks below<\/td><\/tr><\/tbody><\/table><\/figure><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bull_Case_%E2%80%94_What_Has_to_Go_Right_for_Dr_Reddys_Laboratories\"><\/span><strong>Bull Case \u2014 What Has to Go Right for Dr Reddy&#8217;s Laboratories<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"1_Biosimilar_portfolio_Rituximab_Bevacizumab_Filgrastim_ramping_in_US_and_Europe\"><\/span><strong>1. Biosimilar portfolio (Rituximab, Bevacizumab, Filgrastim) ramping in US and Europe<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>$200M+ annualised revenue growing 30%<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2_Siromus_Sirolimus_approved_for_US\"><\/span><strong>2. Siromus (Sirolimus) approved for US<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>next phase of complex generics pipeline<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"3_India_branded_generics_growing_12\"><\/span><strong>3. India branded generics growing 12%<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Dr Reddy&#8217;s is one of India&#8217;s 10 largest pharma companies by prescription market share<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"4_EBITDA_margin_above_25_as_biosimilar_mix_improves\"><\/span><strong>4. EBITDA margin above 25% as biosimilar mix improves<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>highest among large-cap Indian pharma peers<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_At_18x_PE\"><\/span><strong>5. At 18x P\/E<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>among the cheapest large-cap quality pharma stocks<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bear_Case_%E2%80%94_Key_Risks_to_the_Dr_Reddys_Laboratories_Share_Price_Target\"><\/span><strong>Bear Case \u2014 Key Risks to the Dr Reddy&#8217;s Laboratories Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_1_US_generic_price_erosion_continuing_to_pressure_base_business_revenue\"><\/span><strong>Risk 1: US generic price erosion continuing to pressure base business revenue<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>US generic price erosion continuing to pressure base business revenue<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_2_Biosimilar_market_becoming_competitive_as_Biocon_Mylan_and_Pfizer_all_compete_in_same_molecules\"><\/span><strong>Risk 2: Biosimilar market becoming competitive as Biocon, Mylan, and Pfizer all compete in same molecules<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Biosimilar market becoming competitive as Biocon, Mylan, and Pfizer all compete in same molecules<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Institutional_Sentiment_and_Technical_Analysis\"><\/span><strong>Institutional Sentiment and Technical Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Dr Reddy&#8217;s Laboratories has 20.4% FII holding and 22.6% DII holding. High FII ownership of 20.4% means the stock is sensitive to global risk-off events \u2014 FII selling can be disproportionate to any specific negative news.<\/p><p>Technically, Dr Reddy&#8217;s Laboratories is trading at Rs 1,160 against a 52-week range of Rs 1,000 to Rs 1,380. The -10% 1-year return positions the stock in negative territory \u2014 creating both risk of further downside and opportunity for mean reversion. The 12-month analyst target of Rs 1,350-1,600 implies the stock is expected to recover meaningfully from current depressed levels.<\/p><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> for real-time research and analyst updates.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion_%E2%80%94_Our_View_on_name_Share_Price_Target\"><\/span><strong>Conclusion \u2014 Our View on ${name} Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Dr Reddy&#8217;s at Rs 1,160 and 18x P\/E is the most attractively valued large-cap pharma stock in India. The biosimilar platform (Rituximab, Bevacizumab, Filgrastim) is at an inflection point, with revenue growing 30%+ from a meaningful base. At this valuation, the risk-reward is strongly favourable. 12-month target of Rs 1,350-1,600 implies 16-38% upside.<\/p><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Subscribe to Univest Pro for SEBI-registered analyst recommendations \u2014 entry, target, stop-loss.<\/strong><\/a><\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q1_What_is_Dr_Reddys_Laboratories_share_price_target_2026\"><\/span><strong>Q1. What is Dr Reddy&#8217;s Laboratories share price target 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Dr Reddy&#8217;s Laboratories share price target for 2026 is Rs 1,350-1,600 based on analyst consensus. The bull case target is Rs 2,000 and the bear case is Rs 950. These are analyst estimates, not guaranteed returns.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q2_Is_Dr_Reddys_Laboratories_a_good_buy_now\"><\/span><strong>Q2. Is Dr Reddy&#8217;s Laboratories a good buy now?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Dr Reddy&#8217;s Laboratories is trading at Rs 1,160 against a 52-week range of Rs 1,000 to Rs 1,380. Analyst consensus target of Rs 1,350-1,600 implies upside from current levels. Consult a SEBI-registered financial advisor before investing.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q3_What_is_Dr_Reddys_Laboratoriess_current_valuation\"><\/span><strong>Q3. What is Dr Reddy&#8217;s Laboratories&#8217;s current valuation?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Dr Reddy&#8217;s Laboratories trades at a trailing P\/E of 18x and price-to-book of 2.8x with a market capitalisation of Rs 97,000 Cr. The stock&#8217;s valuation relative to earnings growth determines the appropriate entry point.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q4_What_are_the_key_risks_for_Dr_Reddys_Laboratories\"><\/span><strong>Q4. What are the key risks for Dr Reddy&#8217;s Laboratories?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Key risks for Dr Reddy&#8217;s Laboratories include the factors outlined in the Bear Case section of this article. US generic price erosion continuing to pressure base business revenue is the primary near-term risk to watch.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q5_Where_can_I_track_Dr_Reddys_Laboratories_share_price_live\"><\/span><strong>Q5. Where can I track Dr Reddy&#8217;s Laboratories share price live?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Track Dr Reddy&#8217;s Laboratories share price live, quarterly results, FII\/DII activity, and analyst ratings on the Univest Screener at univest.in\/screeners. Download the Univest iOS or Android App for daily research.<\/p><p><strong>Disclaimer: <\/strong>Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All analyst targets are estimates and may change. Verify all numbers before investing. Consult a SEBI-registered financial advisor before making any investment decisions.<\/p><p>For more stock research, visit <a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Articles\"><\/span>Recent Articles<span class=\"ez-toc-section-end\"><\/span><\/h2><p>&nbsp;<a href=\"https:\/\/univest.in\/blogs\/why-is-krbl-share-price-falling\"><strong>Why is KRBL Share Price Falling? Check Next Share Price Target&nbsp;<\/strong><\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-reliance-infrastructures-share-price-falling\"><strong>Why is Reliance Infrastructures Share Price Falling? Check Next Share Price Target&nbsp;<\/strong><\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-mahanagar-gas-share-price-falling\"><strong>Why is Mahanagar Gas Share Price Falling? Check Next Share Price Target&nbsp;<\/strong><\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-happiest-minds-share-price-falling\"><strong>Why is Happiest Minds Share Price Falling? Check Next Share Price Target&nbsp;<\/strong><\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Dr Reddy&#8217;s Laboratories (Pharmaceuticals) is trading at Rs 1,160 as of April 2026, with a 52-week range from Rs 1,000 to Rs 1,380 and a 1-year return of -10%. The analyst consensus 12-month Dr Reddy&#8217;s Laboratories share price target stands at Rs 1,350-1,600 \u2014 implying meaningful potential movement from current levels. Whether you are a<\/p>\n","protected":false},"author":26,"featured_media":70058,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-70054","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"_edit_lock":["1776064486:26"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"rank_math_primary_category":["842"],"rank_math_seo_score":["78"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"rank_math_focus_keyword":["Dr Reddy's Laboratories"],"rank_math_title":[" Dr Reddy's Laboratories Share Price Target 2026: Analyst Estimates, Bull &amp; Bear Case"],"rank_math_description":["Dr Reddy's Laboratories share price target 2026 \u2014 analyst consensus Rs 1,350-1,600. CMP Rs 1,160, 12M target, bull case Rs 2,000, bear case Rs 950. Full analysis.\n"],"_thumbnail_id":["70058"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["7873"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13124154\/dr-reddys-target_.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/70054","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=70054"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/70054\/revisions"}],"predecessor-version":[{"id":70059,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/70054\/revisions\/70059"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/70058"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=70054"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=70054"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=70054"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}